Rolofylline clinical trials
Also written MK7418 and KW-3902IV.
How each study uses rolofylline is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (4) · Merck Sharp & Dohme LLC (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses rolofylline is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)CompletedPhase 2Merck Sharp & Dohme LLCNCT00729222Written as rolofyllineHow we know
- PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal FunctionCompletedPhase 3NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00328692Written as rolofyllineHow we know
- PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal FunctionCompletedPhase 3NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00354458Written as rolofyllineHow we know
- Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV TherapyCompletedPhase 3NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00443690Written as rolofyllineHow we know
- Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure PatientsCompletedPhase 2NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00652782Written as rolofylineHow we know
Codes
What other systems call rolofylline · ClinicalTrials.gg INT003620
- MeSH (NLM) C073525rolofyllineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7805S5HIHXROLOFYLLINEConfirmed FDA, NLM
- NCI Thesaurus C96195RolofyllineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C073525 | rolofylline | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7805S5HIHX | ROLOFYLLINE | Confirmed FDA, NLM |
| NCI Thesaurus | C96195 | Rolofylline | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.